HIV

For over two decades, The President's Emergency Plan for AIDS Relief (PEPFAR) stood as the clearest example of what concentrated donor power could do: one country's political will, translated into billions of dollars a year, credited with saving more lives than any single global health program in history. That era is now ending, not through a managed transition but through an abrupt, largely unplanned withdrawal that began within days of the second Trump administration taking office in January 2025. The story that follows is not simply about cuts to HIV/AIDS funding, but it is about what happens when the architecture of global health financing loses its dominant pillar, who scrambles to fill the resulting vacuum, whether the countries left exposed can build the fiscal and institutional capacity to stand on their own, and whether the system that emerges is more fragile or more resilient than the one it replaces. The transition is already producing real costs: closed clinics, disrupted treatment, and rising infections in countries that had spent years bringing their epidemics under control. Besides, it is also accelerating financing reforms, regional cooperation, and domestic manufacturing that donor dependence had, for twenty years, made largely unnecessary. Both of these things are true at once, and this analysis traces both.